<DOC>
	<DOC>NCT01394029</DOC>
	<brief_summary>This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.</brief_summary>
	<brief_title>Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox</brief_title>
	<detailed_description />
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients treated with deferasirox for transfusional hemosiderosis according to the local prescribing information. (the patients are either beginning treatment with deferasirox at the time of enrollment in the sentinel site monitoring or are currently under treatment with deferasirox and have started the treatment under prescription up to twelve months prior to enrollment in the sentinal site monitoring. Patients with nontransfusional hemosiderosis Patients treated with deferasirox in an interventional clinical trial Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>iron overload</keyword>
	<keyword>iron chelation</keyword>
	<keyword>deferasirox</keyword>
	<keyword>observational</keyword>
</DOC>